Skip to main content
Kimberly Blackwell, MD, Oncology, Durham, NC

KimberlyLBlackwellMD

Oncology Durham, NC

Associate Professor of Medicine, Duke University

Dr. Blackwell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Blackwell's full profile

Already have an account?

  • Office

    Duke Medical Ctr
    # 3893
    Durham, NC 27710
    Phone+1 919-668-1748
    Fax+1 919-681-0874

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Hematology and Medical Oncology, 1997 - 2000
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine, 1994 - 1997
  • Mayo Clinic College of Medicine
    Mayo Clinic College of MedicineClass of 1994

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 1995 - 2025

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2012-2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • America's Top Doctors for Cancer Castle Connolly, 2011-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Individualized Breast, GYN, and Colon Cancer Management; New Data and Updates Relevant to Patient Care 
    Mayo School of Continuous Professional Development, Jacksonville, Florida - 2/15/2013

Press Mentions

  • Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates
    Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational UpdatesNovember 9th, 2022
  • Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates
    Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational UpdatesNovember 9th, 2022
  • Tempus Announces Open Enrollment for Study in Collaboration with GSK to Evaluate Niraparib in Advanced Solid Tumor Patients with PALB2 Mutations
    Tempus Announces Open Enrollment for Study in Collaboration with GSK to Evaluate Niraparib in Advanced Solid Tumor Patients with PALB2 MutationsJanuary 13th, 2022
  • Join now to see all

Professional Memberships